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A 47-year-old white Hispanic man with a never smokinghistory was incidentally found to have a right-sided
pulmonary nodule, hilar, and mediastinal adenopathy. Sam-
pling of level 10R, 11R, and 7 nodal stations disclosed a
carcinoma (Figure 1A) that stained positive, by immunohis-
tochemistry, for thyroid transcription factor 1 (Figure 1B),
transformation-related protein 63 (P63; Figure 1C), and cy-
tokeratin (CK5/6; Figure 1D). By using the newly accepted
International Association for the Study of Lung Cancer
(IASLC)/European Respiratory Society (ERS) classification
for lung cancers, the tumor was best classified as a non-small
cell lung cancer (NSCLC), not otherwise specified1; because
it had both adenocarcinoma (thyroid transcription factor 1)
and squamous cell carcinoma (P63, CK5/6) markers. There
was no evidence of extrathoracic tumor involvement, and the
patient was felt to have stage III NSCLC. The tumor had no
epidermal growth factor receptor or V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog (KRAS) gene mutations. A
break-apart fluorescence in situ hybridization probe for the
anaplastic lymphoma kinase (ALK) demonstrated an ALK
translocation.
ALK translocated NSCLCs account for approximately
5% of all NSCLCs and 20% of NSCLCs from never smok-
ers.2,3 The main clinicopathologic characteristics of these
NSCLCs, to date, include younger age at diagnosis, never or
light smoking history, adenocarcinoma histology, and signet-
ring cells.3 However, tumors with squamous cell carcinoma
or adenosquamous histologies, albeit at a much lower fre-
quency than adenocarcinomas, have been reported to harbor
ALK translocations.4,5 One report described 3 cases on non-
adenocarcinoma (with 1 squamous cell carcinoma and 1
adenosquamous carcinoma) among 82 ALK translocated
NSCLCs,4 and another 1 case of nonadenocarcinoma (1
adenosquamous carcinoma) among 19 ALK translocated
NSCLCs.5 Because the ALK tyrosine kinase inhibitor crizo-
tinib is highly effective in ALK translocated NSCLC,4 it may
be imperative to identify all NSCLCs that harbor ALK trans-
locations in the near future. Our case is instructive and
highlights that tumors with squamous cell carcinoma (P63
and CK5/6) immunohistochemical markers1 also need to be
screened for ALK translocations—especially in never
smokers—if all cases of ALK translocated NSCLC are to
be identified.
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FIGURE 1. A, Level 7 mediastinal
lymph node with carcinoma (hema-
toxylin and eosin). B, Immunohisto-
chemical (IHC) staining for thyroid
transcription factor-1. C, IHC stain-
ing for P63. D, IHC staining for
CK5/6. Magnification, 200.
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